99 related articles for article (PubMed ID: 11295088)
21. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
23. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
24. An experimental study of regional chemotherapy using CDDP-loaded microspheres for esophageal cancer.
Nakamura Y; Hamabe Y; Ikuta H; Hyon SH; Kuroda Y
Surg Today; 2002; 32(4):335-42. PubMed ID: 12027199
[TBL] [Abstract][Full Text] [Related]
25. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
[TBL] [Abstract][Full Text] [Related]
26. Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells.
Toshimitsu H; Hashimoto K; Tangoku A; Iizuka N; Yamamoto K; Kawauchi S; Oga A; Furuya T; Oka M; Sasaki K
Cancer Lett; 2004 Jul; 211(1):69-78. PubMed ID: 15194218
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
[TBL] [Abstract][Full Text] [Related]
28. [Study on changes in plasma platinum concentrations after administration of CDDP to maintenance hemodialysis patients].
Suwata J; Hiraga S; Hida M; Takamiya T; Iida T; Sato T
Gan To Kagaku Ryoho; 1988 Feb; 15(2):243-8. PubMed ID: 3341786
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
30. Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread.
Shigemura N; Akashi A; Nakagiri T; Hazama K; Ohta M; Matsuda H
Ann Thorac Surg; 2004 Mar; 77(3):1016-21; discussion 1021-2. PubMed ID: 14992917
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
Wang S; Mi JB; Li YZ; Chang WB; Ci YX; Zhao MZ; Zhao YK; Zhu LY; Xu G
Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Nakamori M; Iwahashi M; Nakamura M; Yamaue H
J Surg Oncol; 2003 Sep; 84(1):10-6. PubMed ID: 12949985
[TBL] [Abstract][Full Text] [Related]
36. Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis.
Ichinose Y; Yano T; Asoh H; Yokoyama H; Fukuyama Y; Miyagi J; Kuninaka S; Terazaki Y
J Surg Oncol; 1997 Nov; 66(3):196-200. PubMed ID: 9369966
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacokinetic study of intraperitoneally administered plachitin for non-curative gastrointestinal cancer].
Tabara H; Kinugasa S; Tachibana M; Abe S; Yoshimura H; Suzuki K; Monden N; Nakamura T
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1473-6. PubMed ID: 7574735
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.
Monjanel-Mouterde S; Frenay C; Catalin J; Boutin C; Durand A; Astoul P
Oncol Rep; 2000; 7(1):171-5. PubMed ID: 10601613
[TBL] [Abstract][Full Text] [Related]
39. [The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery].
Liu BD; Zhi XY; Xu QS
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(9):586-9. PubMed ID: 15949351
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility.
Abe S; Tokizaki T; Miki Y; Tateishi A; Ogawa K; Nakano H; Matsushita T
Cancer Chemother Pharmacol; 2005 Jul; 56(1):55-62. PubMed ID: 15791455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
